EP2247594A1 - Pyrrolopyrimidincarboxamide - Google Patents

Pyrrolopyrimidincarboxamide

Info

Publication number: EP2247594A1
Authority: EP; European Patent Office
Prior art keywords: hydroxy; pyrrolo; carboxylic acid; pyrinnidine; alkoxy
Prior art date: 2008-02-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP09714992A

Other languages

English (en)

French (fr)

Inventor

Josef Stadlwieser

Beate Schmidt

Heiko Bernsmann

Alexander Sudau

Torsten Dunkern

Degenhard Marx

Jörg DIEFENBACH

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nycomed Asset Management GmbH

Original Assignee

Nycomed GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-02-27

Filing date

2009-02-25

Publication date

2010-11-10

2009-02-25 Application filed by Nycomed GmbH filed Critical Nycomed GmbH

2009-02-25 Priority to EP09714992A priority Critical patent/EP2247594A1/de

2010-11-10 Publication of EP2247594A1 publication Critical patent/EP2247594A1/de

Status Withdrawn legal-status Critical Current

Links

ZYKSLMIKRCOCDC-UHFFFAOYSA-N N1C(C(=O)N)=NC=C2N=CC=C21 Chemical class N1C(C(=O)N)=NC=C2N=CC=C21 ZYKSLMIKRCOCDC-UHFFFAOYSA-N 0.000 title description 4
150000003839 salts Chemical class 0.000 claims abstract description 596
150000001875 compounds Chemical class 0.000 claims abstract description 589
150000001204 N-oxides Chemical class 0.000 claims abstract description 326
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims abstract 2
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims abstract 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 1404
239000001257 hydrogen Substances 0.000 claims description 858
229910052739 hydrogen Inorganic materials 0.000 claims description 858
150000002431 hydrogen Chemical class 0.000 claims description 480
VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical group FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 claims description 394
125000000623 heterocyclic group Chemical group 0.000 claims description 335
MALIONKMKPITBV-UHFFFAOYSA-N 2-(3-chloro-4-hydroxyphenyl)-n-[2-(4-sulfamoylphenyl)ethyl]acetamide Chemical group C1=CC(S(=O)(=O)N)=CC=C1CCNC(=O)CC1=CC=C(O)C(Cl)=C1 MALIONKMKPITBV-UHFFFAOYSA-N 0.000 claims description 295
229910052736 halogen Inorganic materials 0.000 claims description 271
150000002367 halogens Chemical class 0.000 claims description 271
229910052757 nitrogen Inorganic materials 0.000 claims description 174
125000004433 nitrogen atom Chemical group N* 0.000 claims description 174
125000004430 oxygen atom Chemical group O* 0.000 claims description 145
-1 1-formyl-piperidin-4-ylmethyl Chemical group 0.000 claims description 42
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 20
239000008194 pharmaceutical composition Substances 0.000 claims description 6
238000011321 prophylaxis Methods 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 5
238000000034 method Methods 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
125000004356 hydroxy functional group Chemical group O* 0.000 claims 33
BECCHZLFJDWEBQ-LURJTMIESA-N (2s)-1-(4-aminopiperidin-1-yl)-2-hydroxypropan-1-one Chemical compound C[C@H](O)C(=O)N1CCC(N)CC1 BECCHZLFJDWEBQ-LURJTMIESA-N 0.000 claims 15
NLHBHVGPMMXWIM-UHFFFAOYSA-N 1-(4-aminopiperidin-1-yl)ethanone Chemical compound CC(=O)N1CCC(N)CC1 NLHBHVGPMMXWIM-UHFFFAOYSA-N 0.000 claims 14
DGCIBJXJCNPBTN-UHFFFAOYSA-N n-(4-aminocyclohexyl)acetamide Chemical compound CC(=O)NC1CCC(N)CC1 DGCIBJXJCNPBTN-UHFFFAOYSA-N 0.000 claims 11
ARECLULLLYMJKA-UHFFFAOYSA-N 1-(4-aminopiperidin-1-yl)propan-1-one Chemical compound CCC(=O)N1CCC(N)CC1 ARECLULLLYMJKA-UHFFFAOYSA-N 0.000 claims 8
CECNWQFCKPBIGR-NTSWFWBYSA-N (2S)-1-[(3R)-3-aminopyrrolidin-1-yl]-2-hydroxypropan-1-one Chemical compound C[C@H](O)C(=O)N1CC[C@@H](N)C1 CECNWQFCKPBIGR-NTSWFWBYSA-N 0.000 claims 6
XOMJXGKEJVCZEO-UHFFFAOYSA-N 1-(4-aminopiperidin-1-yl)-2-hydroxyethanone Chemical compound NC1CCN(C(=O)CO)CC1 XOMJXGKEJVCZEO-UHFFFAOYSA-N 0.000 claims 6
239000002253 acid Substances 0.000 claims 6
230000001154 acute effect Effects 0.000 claims 6
230000001684 chronic effect Effects 0.000 claims 6
208000023504 respiratory system disease Diseases 0.000 claims 6
GCYSQXZPDQBVCH-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-cyclopropylmethanone Chemical compound C1CC(N)CCN1C(=O)C1CC1 GCYSQXZPDQBVCH-UHFFFAOYSA-N 0.000 claims 5
RCZACEVMRGJMDT-UHFFFAOYSA-N 1-(4-aminopiperidin-1-yl)-2-methoxyethanone Chemical compound COCC(=O)N1CCC(N)CC1 RCZACEVMRGJMDT-UHFFFAOYSA-N 0.000 claims 5
NNAKVSZIWXMNMT-UHFFFAOYSA-N N-(4-aminocyclohexyl)-1-hydroxycyclopropane-1-carboxamide Chemical compound C1CC(N)CCC1NC(=O)C1(O)CC1 NNAKVSZIWXMNMT-UHFFFAOYSA-N 0.000 claims 4
CDIKBRXPAIRDOF-UHFFFAOYSA-N N-(4-aminocyclohexyl)cyclopropanecarboxamide Chemical compound C1CC(N)CCC1NC(=O)C1CC1 CDIKBRXPAIRDOF-UHFFFAOYSA-N 0.000 claims 4
208000019425 cirrhosis of liver Diseases 0.000 claims 4
125000004494 ethyl ester group Chemical group 0.000 claims 4
TXGYDKNMOPOXPR-NKWVEPMBSA-N (2S)-1-[(3R)-3-aminopiperidin-1-yl]-2-hydroxypropan-1-one Chemical compound C[C@H](O)C(=O)N1CCC[C@@H](N)C1 TXGYDKNMOPOXPR-NKWVEPMBSA-N 0.000 claims 3
IVXRSDGVASUAAO-KKMMWDRVSA-N (2S)-N-(4-aminocyclohexyl)-2-hydroxypropanamide Chemical compound C[C@H](O)C(=O)NC1CCC(N)CC1 IVXRSDGVASUAAO-KKMMWDRVSA-N 0.000 claims 3
VUMUXGQOPVYNLU-RXMQYKEDSA-N 1-[(3R)-3-aminopyrrolidin-1-yl]-2-hydroxyethanone Chemical compound N[C@@H]1CCN(C(=O)CO)C1 VUMUXGQOPVYNLU-RXMQYKEDSA-N 0.000 claims 3
238000004519 manufacturing process Methods 0.000 claims 3
DKTIOXTZKAGZJE-UHFFFAOYSA-N n-(4-aminocyclohexyl)-2-hydroxyacetamide Chemical compound NC1CCC(NC(=O)CO)CC1 DKTIOXTZKAGZJE-UHFFFAOYSA-N 0.000 claims 3
SCLWTHCFOIFAIL-UHFFFAOYSA-N n-(4-aminocyclohexyl)-2-methoxyacetamide Chemical compound COCC(=O)NC1CCC(N)CC1 SCLWTHCFOIFAIL-UHFFFAOYSA-N 0.000 claims 3
NWYNDNKIGJDKCN-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-(1-hydroxycyclopropyl)methanone Chemical compound C1CC(N)CCN1C(=O)C1(O)CC1 NWYNDNKIGJDKCN-UHFFFAOYSA-N 0.000 claims 2
RELJROMMAKSPDV-UHFFFAOYSA-N 4-amino-n-cyclopropylcyclohexane-1-carboxamide Chemical compound C1CC(N)CCC1C(=O)NC1CC1 RELJROMMAKSPDV-UHFFFAOYSA-N 0.000 claims 2
IHERZVGWOOXGGV-UHFFFAOYSA-N 4-aminopiperidine-1-carbaldehyde Chemical compound NC1CCN(C=O)CC1 IHERZVGWOOXGGV-UHFFFAOYSA-N 0.000 claims 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
206010014561 Emphysema Diseases 0.000 claims 2
206010067125 Liver injury Diseases 0.000 claims 2
208000006673 asthma Diseases 0.000 claims 2
206010006451 bronchitis Diseases 0.000 claims 2
231100000234 hepatic damage Toxicity 0.000 claims 2
208000006454 hepatitis Diseases 0.000 claims 2
231100000283 hepatitis Toxicity 0.000 claims 2
230000008818 liver damage Effects 0.000 claims 2
208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
208000007232 portal hypertension Diseases 0.000 claims 2
208000005069 pulmonary fibrosis Diseases 0.000 claims 2
208000002815 pulmonary hypertension Diseases 0.000 claims 2
231100000331 toxic Toxicity 0.000 claims 2
230000002588 toxic effect Effects 0.000 claims 2
FTLAFPXLDJTSNF-BYPYZUCNSA-N (2S)-1-(3-aminoazetidin-1-yl)-2-hydroxypropan-1-one Chemical compound C[C@H](O)C(=O)N1CC(N)C1 FTLAFPXLDJTSNF-BYPYZUCNSA-N 0.000 claims 1
TXGYDKNMOPOXPR-BQBZGAKWSA-N (2S)-1-[(3S)-3-aminopiperidin-1-yl]-2-hydroxypropan-1-one Chemical compound C[C@H](O)C(=O)N1CCC[C@H](N)C1 TXGYDKNMOPOXPR-BQBZGAKWSA-N 0.000 claims 1
CECNWQFCKPBIGR-WDSKDSINSA-N (2S)-1-[(3S)-3-aminopyrrolidin-1-yl]-2-hydroxypropan-1-one Chemical compound C[C@H](O)C(=O)N1CC[C@H](N)C1 CECNWQFCKPBIGR-WDSKDSINSA-N 0.000 claims 1
YAQIIQROLMDBSC-UHFFFAOYSA-N 1-(3-aminoazetidin-1-yl)-2-hydroxyethanone Chemical compound NC1CN(C(=O)CO)C1 YAQIIQROLMDBSC-UHFFFAOYSA-N 0.000 claims 1
LFEXNUSBRGBKCT-UHFFFAOYSA-N 1-(3-aminoazetidin-1-yl)-2-methoxyethanone Chemical compound COCC(=O)N1CC(N)C1 LFEXNUSBRGBKCT-UHFFFAOYSA-N 0.000 claims 1
YUJHTWYBKVAQEN-UHFFFAOYSA-N 1-(3-aminoazetidin-1-yl)ethanone Chemical compound CC(=O)N1CC(N)C1 YUJHTWYBKVAQEN-UHFFFAOYSA-N 0.000 claims 1
OVAULDKLSSUUJZ-UHFFFAOYSA-N 1-(3-aminoazetidin-1-yl)propan-1-one Chemical compound CCC(=O)N1CC(N)C1 OVAULDKLSSUUJZ-UHFFFAOYSA-N 0.000 claims 1
KEGNZWDFAVMDJK-UHFFFAOYSA-N 1-(3-aminopiperidin-1-yl)propan-1-one Chemical compound CCC(=O)N1CCCC(N)C1 KEGNZWDFAVMDJK-UHFFFAOYSA-N 0.000 claims 1
SDPGMRYYMHCQKW-SSDOTTSWSA-N 1-[(3R)-3-aminopiperidin-1-yl]-2-methoxyethanone Chemical compound COCC(=O)N1CCC[C@@H](N)C1 SDPGMRYYMHCQKW-SSDOTTSWSA-N 0.000 claims 1
SDPGMRYYMHCQKW-ZETCQYMHSA-N 1-[(3S)-3-aminopiperidin-1-yl]-2-methoxyethanone Chemical compound COCC(=O)N1CCC[C@H](N)C1 SDPGMRYYMHCQKW-ZETCQYMHSA-N 0.000 claims 1
KVYKJACIZCFUOS-ZCFIWIBFSA-N 1-[(3r)-3-aminopiperidin-1-yl]-2-hydroxyethanone Chemical compound N[C@@H]1CCCN(C(=O)CO)C1 KVYKJACIZCFUOS-ZCFIWIBFSA-N 0.000 claims 1
VUMUXGQOPVYNLU-YFKPBYRVSA-N 1-[(3s)-3-aminopyrrolidin-1-yl]-2-hydroxyethanone Chemical compound N[C@H]1CCN(C(=O)CO)C1 VUMUXGQOPVYNLU-YFKPBYRVSA-N 0.000 claims 1
WGUWCGQHJOOCMY-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-fluoro-4-hydroxyphenyl]-N-[1-(2-hydroxyacetyl)piperidin-4-yl]-5H-pyrrolo[3,2-d]pyrimidine-7-carboxamide Chemical compound C1CN(C(=O)CO)CCC1NC(=O)C1=CNC2=C(C=3C(=CC(O)=C(F)C=3)OCC3CC3)N=CN=C12 WGUWCGQHJOOCMY-UHFFFAOYSA-N 0.000 claims 1
INROYTQLALXSMU-UHFFFAOYSA-N 4-[5-(2-methoxyethoxy)-1,3-benzodioxol-4-yl]-5h-pyrrolo[3,2-d]pyrimidine-7-carboxylic acid Chemical compound COCCOC1=CC=C2OCOC2=C1C1=NC=NC2=C1NC=C2C(O)=O INROYTQLALXSMU-UHFFFAOYSA-N 0.000 claims 1
CIJPVKMWDNTXSA-UHFFFAOYSA-N 4-[5-(cyclopropylmethoxy)-1,3-benzodioxol-4-yl]-n-[(1-formylpyrrolidin-3-yl)methyl]-5h-pyrrolo[3,2-d]pyrimidine-7-carboxamide Chemical compound C1N(C=O)CCC1CNC(=O)C1=CNC2=C(C=3C(=CC=C4OCOC4=3)OCC3CC3)N=CN=C12 CIJPVKMWDNTXSA-UHFFFAOYSA-N 0.000 claims 1
DDEYDVQFTXESHX-OAHLLOKOSA-N 4-[5-(cyclopropylmethoxy)-1,3-benzodioxol-4-yl]-n-[(3r)-1-(2-methoxyacetyl)pyrrolidin-3-yl]-5h-pyrrolo[3,2-d]pyrimidine-7-carboxamide Chemical compound C1N(C(=O)COC)CC[C@H]1NC(=O)C1=CNC2=C(C=3C(=CC=C4OCOC4=3)OCC3CC3)N=CN=C12 DDEYDVQFTXESHX-OAHLLOKOSA-N 0.000 claims 1
PDYNAAMZBDUKCI-IYARVYRRSA-N C1(CC1)C(=O)N[C@@H]1CC[C@H](CC1)NC(=O)C1=CNC2=C1N=CN=C2C1=C(C=C(C=C1)OC)OCCOC Chemical compound C1(CC1)C(=O)N[C@@H]1CC[C@H](CC1)NC(=O)C1=CNC2=C1N=CN=C2C1=C(C=C(C=C1)OC)OCCOC PDYNAAMZBDUKCI-IYARVYRRSA-N 0.000 claims 1
PMYNIKFKHDRYIX-IYARVYRRSA-N C1(CC1)C(=O)N[C@@H]1CC[C@H](CC1)NC(=O)C1=CNC2=C1N=CN=C2C1=C(C=CC=2OCOC=21)OCC1CC1 Chemical compound C1(CC1)C(=O)N[C@@H]1CC[C@H](CC1)NC(=O)C1=CNC2=C1N=CN=C2C1=C(C=CC=2OCOC=21)OCC1CC1 PMYNIKFKHDRYIX-IYARVYRRSA-N 0.000 claims 1
229940127291 Calcium channel antagonist Drugs 0.000 claims 1
102000002045 Endothelin Human genes 0.000 claims 1
108050009340 Endothelin Proteins 0.000 claims 1
QTYGXDUXIZLHGI-SSDOTTSWSA-N [(3R)-3-aminopyrrolidin-1-yl]-cyclopropylmethanone Chemical compound C1[C@H](N)CCN1C(=O)C1CC1 QTYGXDUXIZLHGI-SSDOTTSWSA-N 0.000 claims 1
239000000808 adrenergic beta-agonist Substances 0.000 claims 1
239000005557 antagonist Substances 0.000 claims 1
239000003242 anti bacterial agent Substances 0.000 claims 1
229940088710 antibiotic agent Drugs 0.000 claims 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
239000000935 antidepressant agent Substances 0.000 claims 1
229940005513 antidepressants Drugs 0.000 claims 1
239000002876 beta blocker Substances 0.000 claims 1
229940097320 beta blocking agent Drugs 0.000 claims 1
230000003454 betamimetic effect Effects 0.000 claims 1
239000000480 calcium channel blocker Substances 0.000 claims 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
239000000812 cholinergic antagonist Substances 0.000 claims 1
239000003246 corticosteroid Substances 0.000 claims 1
229960001334 corticosteroids Drugs 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
210000004072 lung Anatomy 0.000 claims 1
GSSCAZQCMWVCKJ-UHFFFAOYSA-N n-(1-acetylpiperidin-4-yl)-4-[5-(cyclopropylmethoxy)-1,3-benzodioxol-4-yl]-5h-pyrrolo[3,2-d]pyrimidine-7-carboxamide Chemical compound C1CN(C(=O)C)CCC1NC(=O)C1=CNC2=C(C=3C(=CC=C4OCOC4=3)OCC3CC3)N=CN=C12 GSSCAZQCMWVCKJ-UHFFFAOYSA-N 0.000 claims 1
IAVPHIVKUVLWMT-UHFFFAOYSA-N n-(1-propanoylpiperidin-4-yl)-4-(5-propoxy-1,3-benzodioxol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-7-carboxamide Chemical compound CCCOC1=CC=C2OCOC2=C1C(C=1NC=2)=NC=NC=1C=2C(=O)NC1CCN(C(=O)CC)CC1 IAVPHIVKUVLWMT-UHFFFAOYSA-N 0.000 claims 1
239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
150000003815 prostacyclins Chemical class 0.000 claims 1
239000004094 surface-active agent Substances 0.000 claims 1
229940124597 therapeutic agent Drugs 0.000 claims 1
239000003112 inhibitor Substances 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1293
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 274
125000004435 hydrogen atom Chemical group [H]* 0.000 description 105
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 35
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 16
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 11
239000011737 fluorine Substances 0.000 description 11
229910052731 fluorine Inorganic materials 0.000 description 11
125000004432 carbon atom Chemical group C* 0.000 description 7
125000000217 alkyl group Chemical group 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
125000003725 azepanyl group Chemical group 0.000 description 2
125000002393 azetidinyl group Chemical group 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
125000000753 cycloalkyl group Chemical group 0.000 description 2
125000002757 morpholinyl group Chemical group 0.000 description 2
125000003386 piperidinyl group Chemical group 0.000 description 2
125000000719 pyrrolidinyl group Chemical group 0.000 description 2
125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000006637 cyclobutyl carbonyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000006328 iso-butylcarbonyl group Chemical group [H]C([H])([H])C([H])(C(*)=O)C([H])([H])[H] 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000006257 n-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])OC(*)=O 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000006252 n-propylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
125000006256 n-propyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC(*)=O 0.000 description 1
125000005961 oxazepanyl group Chemical group 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Definitions

the invention relates to pyrrolopyrimidinecarboxamide compounds, processes for their preparation, pharmaceutical compositions comprising said compounds and the use thereof in the treatment or prophylaxis of diseases.
the invention relates to compounds of formula (I)
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen, - 2 -
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy, R72 is 1-4C-alkoxy or hydroxy, R73 is 1-4C-alkoxy or hydroxy
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, which is optionally substituted by R92,
R91 is 1-4C-alkoxy or hydroxy
R92 is 1-4C-alkoxy or hydroxy, salts thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
1-4C-Alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms. Examples are methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl and tert-butyl.
Halogen includes fluorine, chlorine, bromine and iodine. In case of R22 and/or R23 being halogen, fluorine is preferred.
3-6C-Cycloalkyl is a cycloalkyl group having 3 to 6 carbon atoms, examples of which include the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl group.
R3 being 3-6C-cycloalkyl, cyclohexyl is preferred.
1-4C-Alkoxy represents a group which, in addition to the oxygen atom, contains a straight-chain or branched alkyl moiety having 1 to 4 carbon atoms. Examples are methoxy, ethoxy, n-propoxy, iso- propoxy, n-butoxy, iso-butoxy, sec-butoxy and tert-butoxy. - 3 -
1-4C-Fluoroalkoxy represents a group which, in addition to the oxygen atom, contains a straight- chain or branched alkyl moiety having 1 to 4 carbon atoms, wherein one or more of the hydrogen atoms of the alkyl moiety are replaced by fluorine.
Examples include, but are not limited to, a trifluoromethoxy, difluoromethoxy, fluoromethoxy, perfluoroethoxy, 1 ,1 ,1-trifluoro-2-fluoroethoxy, 1 ,1 ,1-trifluoroethoxy, 1 ,1-difluoro-2,2-difluoroethoxy, 1 ,1-difluoro-2-fluoroethoxy, 1 ,1-difluoroethoxy, 1-fluoro-2,2-difluoroethoxy, 1-fluoro-2-fluoroethoxy, 1-fluoroethoxy, 2,2-difluoroethoxy, 2- fluoroethoxy, n-perfluoropropoxy, and n-perfluorobutoxy group.
the group -C(O)-I -4C-alkyl represents a group which, in addition to the carbonyl group -C(O)-, contains a straight-chain or branched alkyl moiety having 1 to 4 carbon atoms. Examples are methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, iso-propylcarbonyl, n-butylcarbonyl, iso-butylcarbonyl, sec-butylcarbonyl and tert-butylcarbonyl.
the group -C(O)-3-6C-cycloalkyl represents a group which, in addition to the carbonyl group -C(O)-, contains a cycloalkyl group having 3 to 6 carbon atoms. Examples are cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl and cyclohexylcarbonyl.
the group -C(O)-O-I -4C-alkyl represents a group which, in addition to the oxycarbonyl group -C(O)-O-, contains a straight-chain or branched alkyl moiety having 1 to 4 carbon atoms. Examples are methyloxycarbonyl, ethyloxycarbonyl, n-propyloxycarbonyl, iso-propyloxycarbonyl, n- butyloxycarbonyl, iso-butyloxycarbonyl, sec-butyloxycarbonyl and tert-butyloxycarbonyl.
the 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom includes, but is not limited to, azetidinyl, oxazetidinyl, pyrrolidinyl, oxazolidinyl, piperidinyl, morpholinyl, azepanyl and oxazepanyl, in particular azetidinyl, 1 ,3-oxazetidinyl, pyrrolidinyl, 1 ,3-oxazolidinyl, piperidinyl, morpholinyl, azepanyl and 1 ,3-oxazepanyl, preferably azetidin-3-yl, pyrrolidin-3-yl, morpholin-2-yl, piperidin-3-yl and piperidin-4-yl.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-4C-cycloalkyl or 2-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy,
R24 is hydrogen
Y is -(CH 2 J n -, - A -
n 0 or 1
R3 is a 4- to 6-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy, R42 is 1-4C-alkoxy or hydroxy, R43 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-4C-cycloalkyl
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy,
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy, - 5 -
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, which is optionally substituted by R92, R91 is 1-4C-alkoxy or hydroxy, R92 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3-6C-cycloalkyl, which is optionally substituted by R92, - 6 -
R91 is 1-4C-alkoxy or hydroxy
R92 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is 3-4C-alkyl which is optionally substituted by R11 ,
R11 is methoxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-, R24 is hydrogen,
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy,
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof. - 7 -
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen, R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-, R24 is hydrogen,
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 6-membered saturated heterocyclic ring containing one nitrogen atom, said heterocyclic ring being optionally substituted by R4,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
a salt thereof an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-4C-cycloalkyl or 2-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CHz) n -, n is 0 or 1 ,
R3 is a 4- to 6-membered saturated heterocyclic ring containing one nitrogen atom, said heterocyclic ring being substituted by R4, - 8 -
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-4C-cycloalkyl or 2-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen, Y is -(CHz) n -, n is 0 or 1 ,
R3 is a 3-6C-cycloalkyl group substituted by R6,
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91
3- ⁇ C-cycloalkyl which is optionally substituted by R92
R91 is 1-4C-alkoxy or hydroxy
R92 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-4C-cycloalkyl or 2-4C-alkyl which is optionally substituted by R11 , - 9 -
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 , R3 is a cyclohexyl group substituted by R6,
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, which is optionally substituted by R92, R91 is 1-4C-alkoxy or hydroxy,
R92 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen, Y is -(CHz) n -, n is 0 or 1 ,
R3 is a 4- to 6-membered saturated heterocyclic ring containing one nitrogen atom and one oxygen atom, said heterocyclic ring being optionally substituted by R4, - 10 -
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-4C-cycloalkyl or 2-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen, Y is -(CHz) n -, n is 0 or 1 ,
R3 is a 4- to 6-membered saturated heterocyclic ring containing one nitrogen atom and one oxygen atom, said heterocyclic ring being substituted by R4,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen,
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, - 11 -
R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen, Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 5- to 6-membered saturated heterocyclic ring containing one nitrogen atom, said heterocyclic ring being substituted by R4,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy,
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-, R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CHz) n -, n is 0 or 1 , R3 is a 5-membered saturated heterocyclic ring containing one nitrogen atom, said heterocyclic ring being substituted by R4,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy,
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy, - 12 -
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen, R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-, R24 is hydrogen,
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 6-membered saturated heterocyclic ring containing one nitrogen atom, said heterocyclic ring being substituted by R4,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CHz) n -, n is 0 or 1 , - 13 -
R3 is a 6-nnennbered saturated heterocyclic ring containing one nitrogen atom and one oxygen atom, said heterocyclic ring being substituted by R4, R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 ,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
a salt thereof an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or -C(O)-I -4C-alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy or hydroxy, or R22 and R23 combine to form a group -0-CH 2 -O-, R24 is hydrogen,
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 3-6C-cycloalkyl group substituted by R6,
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, which is optionally substituted by R92,
R91 is 1-4C-alkoxy or hydroxy
R92 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein - 14 -
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen,
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or -C(O)-I -4C-alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy or hydroxy, or R22 and R23 combine to form a group -0-CH 2 -O-, R24 is hydrogen,
Y is -(CH 2 J n -, n is O or i ,
R3 is a cyclohexyl group substituted by R6,
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy,
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CHz) n -, n is 0,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6, - 15 -
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy,
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3-6C-cycloalkyl, which is optionally substituted by R92,
R91 is 1-4C-alkoxy or hydroxy
R92 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen, R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-, R24 is hydrogen, Y is -(CH 2 J n -, n is 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 ,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, which is optionally substituted by R92,
R91 is 1-4C-alkoxy or hydroxy
R92 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy,
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-, R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy,
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 , - 17 -
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, which is optionally substituted by R92,
R91 is 1-4C-alkoxy or hydroxy
R92 is 1-4C-alkoxy or hydroxy
a salt thereof an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy
R24 is hydrogen
Y is -(CHz) n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy, R42 is 1-4C-alkoxy or hydroxy, R43 is 1-4C-alkoxy or hydroxy,
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy, R72 is 1-4C-alkoxy or hydroxy, R73 is 1-4C-alkoxy or hydroxy, R8 is hydrogen, - 18 -
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, which is optionally substituted by R92, R91 is 1-4C-alkoxy or hydroxy, R92 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy,
R21 , R22, R23 and R24 are each hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy,
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen, - 19 -
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-, R23 is 1-4C-alkoxy, R24 is hydrogen,
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy,
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydroxy
R24 is hydrogen
Y is -(CH 2 J n -, - 20 -
n 0 or 1
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 ,
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy, R72 is 1-4C-alkoxy or hydroxy, R73 is 1-4C-alkoxy or hydroxy, R8 is hydrogen,
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy,
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-, R23 is 1-4C-fluoroalkoxy,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy, R42 is 1-4C-alkoxy or hydroxy, R43 is 1-4C-alkoxy or hydroxy, R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 , R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optional
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3-6C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is halogen
R23 is 1-4C-alkoxy
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 , - 22 -
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy, R72 is 1-4C-alkoxy or hydroxy, R73 is 1-4C-alkoxy or hydroxy, R8 is hydrogen,
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is -C(O)-I -4C-alkyl
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, - 23 -
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is halogen
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy,
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen, R22 is 1-4C-alkoxy, - 24 -
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1
R3 is a 4- to 7-mennbered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 ,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen, R22 is hydroxy,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy,
R24 is hydrogen
Y is -(CHz) n -, n is 0 or 1
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6, - 25 -
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy, R42 is 1-4C-alkoxy or hydroxy, R43 is 1-4C-alkoxy or hydroxy, R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 , R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optional
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3-6C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is 1-4C-fluoroalkoxy
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 , - 26 -
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy, R72 is 1-4C-alkoxy or hydroxy, R73 is 1-4C-alkoxy or hydroxy, R8 is hydrogen,
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is 1-4C-alkoxy
R23 is halogen
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, - 27 -
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is 1-4C-alkyl
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy,
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 and R22 combine to form a group -0-CH 2 -O-, R23 is hydrogen, - 28 -
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-nnennbered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy, R42 is 1-4C-alkoxy or hydroxy, R43 is 1-4C-alkoxy or hydroxy, R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, which is optionally substituted by R92
R91 is 1-4C-alkoxy or hydroxy
R92 is 1-4C-alkoxy or hydroxy
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is halogen
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 , - 29 -
R3 is a 4- to 7-nnennbered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy, R42 is 1-4C-alkoxy or hydroxy, R43 is 1-4C-alkoxy or hydroxy, R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy, R72 is 1-4C-alkoxy or hydroxy, R73 is 1-4C-alkoxy or hydroxy, R8 is hydrogen,
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen,
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-, R23 and R24 are hydrogen, Y is -(CH 2 ) n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 ,
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3-6C-cycloalkyl
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is fluorine
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy,
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy, - 31 -
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is methoxy
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , - 32 -
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is methyl
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-mennbered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy,
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is methylcarbonyl
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 , - 33 -
R3 is a 4- to 7-nnennbered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy, R42 is 1-4C-alkoxy or hydroxy, R43 is 1-4C-alkoxy or hydroxy, R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy, R72 is 1-4C-alkoxy or hydroxy, R73 is 1-4C-alkoxy or hydroxy, R8 is hydrogen,
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen,
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-, R23 is fluorine, R24 is hydrogen, Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 ,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen, R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-, R23 is methoxy, R24 is hydrogen, Y is -(CH 2 ) n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 ,
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, - 35 -
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl
R91 is 1-4C-alkoxy or hydroxy
a salt thereof an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is methoxy
R23 is fluorine
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy,
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof. - 36 -
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is fluorine
R23 is methoxy
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen,
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-, - 37 -
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-, R24 is hydrogen,
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CHz) n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , R41 is 1-4C-alkoxy or hydroxy, - 38 -
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy, R72 is 1-4C-alkoxy or hydroxy, R73 is 1-4C-alkoxy or hydroxy, R8 is hydrogen,
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy,
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-, R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by
R42, R42 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, - 39 -
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen, Y is -(CHz) n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6, R4 is -C(O)-O-1-4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy,
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen, - 40 -
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-O-1-4C-alkyl
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen, Y is -(CHz) n -, n is 0 or 1 , - 41 -
R3 is a 4- to 7-nnennbered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , R41 is 1-4C-alkoxy,
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy,
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-, R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-2-4C-alkyl, wherein the 2-4C-alkyl group is optionally substituted by R41 ,
R41 is methoxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy, - 42 -
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-2-4C-alkyl, wherein the 2-4C-alkyl group is optionally substituted by R41 , R41 is hydroxy,
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein - 43 -
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen, Y is -(CHz) n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6, R4 is -C(O)-cyclopropyl, wherein the cyclopropyl group is optionally substituted by R42,
R42 is 1-4C-alkoxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy,
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen, - 44 -
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-cyclopropyl, wherein the cyclopropyl group is optionally substituted by R42,
R42 is methoxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen, Y is -(CHz) n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6, R4 is -C(O)-cyclopropyl, wherein the cyclopropyl group is optionally substituted by R42,
R42 is hydroxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 , - 45 -
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy, R72 is 1-4C-alkoxy or hydroxy, R73 is 1-4C-alkoxy or hydroxy, R8 is hydrogen,
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 -C(O)-O-I -4C-alkyl which is optionally substituted by R43,
R43 is 1-2C-alkoxy
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, - 46 -
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 -C(O)-O-I -4C-alkyl which is optionally substituted by R43, R43 is methoxy
R6 is -NH-C(O)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen,
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, - 47 -
R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen, Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6, R4 -C(O)-O-I -4C-alkyl, which is optionally substituted by R43,
R43 is hydroxy
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy,
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CHz) n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6, - 48 -
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(0)-R7
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73, R71 is 1-4C-alkoxy or hydroxy,
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-, R24 is hydrogen,
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -C(O)-NR8R9
R8 is hydrogen, - 49 -
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-, R24 is hydrogen,
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(0)-R7
R7 is 1-2C-alkyl, which is optionally substituted by R71 ,
R71 is 1-2C-alkoxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, - 50 -
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-, R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-, R24 is hydrogen,
Y is -(CH 2 J n -, n is 0 or 1
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(0)-R7, R7 is 1-2C-alkyl, which is optionally substituted by R71 ,
R71 is hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy,
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-, R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CHz) n -, - 51 -
n 0 or 1
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 ,
R7 is cyclopropyl, which is optionally substituted by R72, R72 is 1-2C-alkoxy, R8 is hydrogen, R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen,
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-, R24 is hydrogen, Y is -(CHz) n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy, - 52 -
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7
R7 is cyclopropyl, which is optionally substituted by R72, R72 is hydroxy, R8 is hydrogen,
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl, R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy,
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(0)-R7
R7 is 1-2C-alkoxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3-6C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, - 53 -
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -2C-alkyl, wherein the 1-2C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2 ,
R7 is 1-4C-alkyl, which is optionally substituted by R71 , 3- ⁇ C-cycloalkyl, which is optionally substituted by R72, or 1-2C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl,
R91 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , - 54 -
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-, R24 is hydrogen, Y is -(CH 2 J n -, n is O or i ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , or -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(0)-R7, -C(O)-NR8R9 or NH 2
R7 is 1-4C-alkyl, which is optionally substituted by R71 , or 3-6C-cycloalkyl, which is optionally substituted by R72
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl
R91 is 1-4C-alkoxy or hydroxy
salts thereof an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-, - 55 -
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 7-nnennbered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy,
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7 or -C(O)-NR8R9
R7 is hydrogen, 1-4C-alkyl, which is optionally substituted by R71 , 3-6C-cycloalkyl, which is optionally substituted by R72, or 1-4C-alkoxy, which is optionally substituted by R73,
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R73 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl
R91 is 1-4C-alkoxy or hydroxy, salts thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen, Y is -(CHz) n -, n is 0 or 1 , - 56 -
R3 is a 4- to 7-nnennbered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , or -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R6 is -NH-C(O)-R7 or -C(O)-NR8R9
R7 is 1-4C-alkyl, which is optionally substituted by R71 , or 3- ⁇ C-cycloalkyl, which is optionally substituted by R72
R71 is 1-4C-alkoxy or hydroxy
R72 is 1-4C-alkoxy or hydroxy
R8 is hydrogen
R9 is 1-4C-alkyl, which is optionally substituted by R91 , or 3- ⁇ C-cycloalkyl
R91 is 1-4C-alkoxy or hydroxy
salts thereof an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy, R21 is hydrogen,
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-, R24 is hydrogen, Y is -(CHz) n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43, R41 is 1-4C-alkoxy or hydroxy, - 57 -
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -C(O)-NR8R9
R8 is hydrogen
R9 is 1-2C-alkyl, which is optionally substituted by R91
R91 is 1-2C-alkoxy
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen, Y is -(CHz) n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -C(O)-NR8R9
R8 is hydrogen
R9 is 1-2C-alkyl, which is optionally substituted by R91 ,
R91 is hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein - 58 -
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen, Y is -(CHz) n -, n is 0 or 1 ,
R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, or a 3-6C-cycloalkyl group substituted by R6,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy
R6 is -C(O)-NR8R9
R8 is hydrogen
R9 is cyclopropyl, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 ,
R11 is 1-4C-alkoxy or hydroxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1 , - 59 -
R3 is a 4- to 6-nnennbered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4, wherein R4, if present, is bonded to said nitrogen atom,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11 , R11 is 1-4C-alkoxy or hydroxy,
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-, R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-,
R24 is hydrogen
Y is -(CH 2 J n -, n is 0 or 1
R3 is a 4- to 6-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being substituted by R4 at said nitrogen atom
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy, a salt thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein R1 is -CH 2 -3-4C-cycloalkyl or 2-4C-alkyl which is optionally substituted by R11 , - 60 -
R11 is 1-4C-alkoxy
R21 is hydrogen
R22 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy or -C(O)-I -4C- alkyl, or R21 and R22 combine to form a group -0-CH 2 -O-,
R23 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, hydroxy or 1-4C-fluoroalkoxy, or R22 and R23 combine to form a group -0-CH 2 -O-, R24 is hydrogen,
Y is -(CH 2 J n -, n is 0 or 1 ,
R3 is a 4- to 6-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being substituted by R4 at said nitrogen atom,
R4 is -C(O)-H, -C(O)-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R41 , -C(O)-3-6C-cycloalkyl, wherein the 3-6C-cycloalkyl group is optionally substituted by R42, or -C(O)-O-I -4C-alkyl, wherein the 1-4C-alkyl group is optionally substituted by R43,
R41 is 1-4C-alkoxy or hydroxy
R42 is 1-4C-alkoxy or hydroxy
R43 is 1-4C-alkoxy or hydroxy, salts thereof, an N-oxide of the compound or the salt thereof and a stereoisomer of the compound, the salt, the N-oxide of the compound or the N-oxide of the salt thereof.
the invention relates to compounds of formula (I), wherein
R1 is -CH 2 -3-4C-cycloalkyl
R21 is hydrogen
R22 is hydrogen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP09714992A 2008-02-27 2009-02-25 Pyrrolopyrimidincarboxamide Withdrawn EP2247594A1 (de)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP09714992A EP2247594A1 (de)	2008-02-27	2009-02-25	Pyrrolopyrimidincarboxamide

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08102052		2008-02-27
EP09714992A EP2247594A1 (de)	2008-02-27	2009-02-25	Pyrrolopyrimidincarboxamide
PCT/EP2009/052198 WO2009106531A1 (en)	2008-02-27	2009-02-25	Pyrrolopyrimidinecarboxamides

Publications (1)

Publication Number	Publication Date
EP2247594A1 true EP2247594A1 (de)	2010-11-10

Family

ID=39855184

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP09714992A Withdrawn EP2247594A1 (de)	2008-02-27	2009-02-25	Pyrrolopyrimidincarboxamide

Country Status (20)

Country	Link
US (1)	US8445501B2 (de)
EP (1)	EP2247594A1 (de)
JP (1)	JP5615187B2 (de)
KR (1)	KR20100136469A (de)
CN (1)	CN101959890B (de)
AR (1)	AR070454A1 (de)
AU (1)	AU2009218507B2 (de)
BR (1)	BRPI0907863A2 (de)
CA (1)	CA2711733A1 (de)
CO (1)	CO6341477A2 (de)
EA (1)	EA018331B1 (de)
EC (1)	ECSP10010425A (de)
IL (1)	IL207639A (de)
MX (1)	MX2010009276A (de)
MY (1)	MY152061A (de)
NZ (1)	NZ586486A (de)
SG (1)	SG188823A1 (de)
TW (1)	TW200944527A (de)
UA (1)	UA101018C2 (de)
WO (1)	WO2009106531A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ600238A (en)	2008-06-19	2014-04-30	Takeda Pharmaceutical	Heterocyclic compound and use thereof
JP5685181B2 (ja)	2009-03-05	2015-03-18	塩野義製薬株式会社	Ｎｐｙｙ５受容体拮抗作用を有するシクロヘキサン誘導体
AR077898A1 (es) *	2009-08-26	2011-09-28	Nycomed Gmbh	Metilpirrolopirimidincarboxamidas
US8816085B2 (en) *	2009-08-26	2014-08-26	Takeda Gmbh	Methylpyrrolopyridinecarboxamides
CN103201244B (zh) *	2010-08-26	2015-06-17	阿尔比马尔公司	用于制备1-溴代-2-(环丙基甲氧基)-5-氟代-4-甲氧基苯的方法
US20140112945A1 (en)	2011-06-17	2014-04-24	Takeda Gmbh	Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
US10527935B2 (en)	2016-12-31	2020-01-07	Rohm And Haas Electronic Materials Llc	Radiation-sensitive compositions and patterning and metallization processes
JP2020097527A (ja) *	2017-03-31	2020-06-25	武田薬品工業株式会社	複素環化合物
WO2019007299A1 (zh)	2017-07-07	2019-01-10	中国科学院上海药物研究所	一种苯基嘧啶酮化合物的盐、多晶型物及其药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2754260B1 (fr) *	1996-10-04	1998-10-30	Adir	Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6187777B1 (en) *	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
US20050124623A1 (en) *	2003-11-26	2005-06-09	Bender John A.	Diazaindole-dicarbonyl-piperazinyl antiviral agents
CA2599368A1 (en) *	2005-03-09	2006-09-14	Nycomed Gmbh	Amido-substituted 6-phenylphenanthridines

2009
- 2009-02-20 AR ARP090100594A patent/AR070454A1/es unknown
- 2009-02-25 EA EA201001348A patent/EA018331B1/ru not_active IP Right Cessation
- 2009-02-25 JP JP2010548092A patent/JP5615187B2/ja not_active Expired - Fee Related
- 2009-02-25 MX MX2010009276A patent/MX2010009276A/es active IP Right Grant
- 2009-02-25 NZ NZ586486A patent/NZ586486A/en not_active IP Right Cessation
- 2009-02-25 CN CN2009801072042A patent/CN101959890B/zh not_active Expired - Fee Related
- 2009-02-25 SG SG2013014634A patent/SG188823A1/en unknown
- 2009-02-25 KR KR1020107021192A patent/KR20100136469A/ko not_active Ceased
- 2009-02-25 BR BRPI0907863A patent/BRPI0907863A2/pt not_active IP Right Cessation
- 2009-02-25 US US12/918,740 patent/US8445501B2/en not_active Expired - Fee Related
- 2009-02-25 MY MYPI20103000 patent/MY152061A/en unknown
- 2009-02-25 CA CA2711733A patent/CA2711733A1/en not_active Abandoned
- 2009-02-25 AU AU2009218507A patent/AU2009218507B2/en not_active Ceased
- 2009-02-25 EP EP09714992A patent/EP2247594A1/de not_active Withdrawn
- 2009-02-25 WO PCT/EP2009/052198 patent/WO2009106531A1/en not_active Ceased
- 2009-02-25 UA UAA201011254A patent/UA101018C2/ru unknown
- 2009-02-26 TW TW098106249A patent/TW200944527A/zh unknown
2010
- 2010-06-15 CO CO10071529A patent/CO6341477A2/es active IP Right Grant
- 2010-08-16 IL IL207639A patent/IL207639A/en not_active IP Right Cessation
- 2010-08-25 EC EC2010010425A patent/ECSP10010425A/es unknown

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009106531A1 *

Also Published As

Publication number	Publication date
HK1153200A1 (en)	2012-03-23
AU2009218507B2 (en)	2014-02-13
US20110021479A1 (en)	2011-01-27
AU2009218507A1 (en)	2009-09-03
IL207639A (en)	2013-09-30
EA201001348A1 (ru)	2011-04-29
WO2009106531A1 (en)	2009-09-03
MY152061A (en)	2014-08-15
CA2711733A1 (en)	2009-09-03
UA101018C2 (ru)	2013-02-25
TW200944527A (en)	2009-11-01
KR20100136469A (ko)	2010-12-28
EA018331B1 (ru)	2013-07-30
CN101959890B (zh)	2013-10-30
US8445501B2 (en)	2013-05-21
SG188823A1 (en)	2013-04-30
JP5615187B2 (ja)	2014-10-29
CO6341477A2 (es)	2011-11-21
AR070454A1 (es)	2010-04-07
ECSP10010425A (es)	2010-09-30
JP2011513272A (ja)	2011-04-28
BRPI0907863A2 (pt)	2019-09-24
NZ586486A (en)	2012-06-29
IL207639A0 (en)	2010-12-30
MX2010009276A (es)	2010-09-14
CN101959890A (zh)	2011-01-26

Legal Events

Date	Code	Title	Description
2010-10-08	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2010-11-10	17P	Request for examination filed	Effective date: 20100927
2010-11-10	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
2010-11-10	AX	Request for extension of the european patent	Extension state: AL BA RS
2011-06-01	DAX	Request for extension of the european patent (deleted)
2012-02-15	RIN1	Information on inventor provided before grant (corrected)	Inventor name: DIEFENBACH, JOERG Inventor name: MARX, DEGENHARD Inventor name: DUNKERN, TORSTEN Inventor name: SUDAU, ALEXANDER Inventor name: BERNSMANN, HEIKO Inventor name: SCHMIDT, BEATE Inventor name: STADLWIESER, JOSEF
2013-04-03	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: TAKEDA GMBH
2013-12-04	RIN1	Information on inventor provided before grant (corrected)	Inventor name: SCHMIDT, BEATE Inventor name: STADLWIESER, JOSEF Inventor name: MARX, DEGENHARD Inventor name: BERNSMANN, HEIKO Inventor name: DUNKERN, TORSTEN Inventor name: DIEFENBACH, JOERG Inventor name: SUDAU, ALEXANDER
2014-10-22	RIN1	Information on inventor provided before grant (corrected)	Inventor name: BERNSMANN, HEIKO Inventor name: SCHMIDT, BEATE Inventor name: STADLWIESER, JOSEF Inventor name: MARX, DEGENHARD Inventor name: SUDAU, ALEXANDER Inventor name: DUNKERN, TORSTEN Inventor name: DIEFENBACH, JOERG
2015-03-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
2015-04-29	18W	Application withdrawn	Effective date: 20150326
2015-06-03	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: NYCOMED ASSET MANAGEMENT GMBH
2015-06-10	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: NYCOMED GERMANY HOLDING GMBH
2015-06-24	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: TAKEDA GMBH

Publication	Publication Date	Title
AU2009218507B2 (en)	2014-02-13	Pyrrolopyrimidinecarboxamides
EP3464245B1 (de)	2020-10-14	Benzazepindicarboxamidverbindungen mit tertiärer amidfunktion
EP2035427B1 (de)	2013-12-11	Pyrazolo[1,5-a]pyrimidinverbindungen als cb1-rezeptorantagonisten
WO2020047198A1 (en)	2020-03-05	Salts of an lsd1 inhibitor and processes for preparing the same
JP2018141020A (ja)	2018-09-13	Ｊａｋ阻害薬としての三環式縮合チオフェン誘導体
KR20230057386A (ko)	2023-04-28	Apol1 억제제 및 사용 방법
EP1552842A1 (de)	2005-07-13	Bizyklische pyrimidin-derivate
WO2013173720A1 (en)	2013-11-21	Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US20240368120A1 (en)	2024-11-07	Compounds as glp-1r agonists
EP2109610A1 (de)	2009-10-21	6-benzyl-2,3,4,7-tetrahydro-indol[2-c]chinolin-verbindungen als pde5-hemmer
TWI471327B (zh)	2015-02-01	甲基吡咯嘧啶甲醯胺
WO2011015523A1 (en)	2011-02-10	Benzyl-substituted tetracyclic heterocyclic compounds
US8816085B2 (en)	2014-08-26	Methylpyrrolopyridinecarboxamides
HK1153200B (en)	2014-06-20	Pyrrolopyrimidinecarboxamides
CN121021476A (zh)	2025-11-28	吡嗪甲酰胺类化合物及其制备方法、药物组合物和应用
JP2003183278A (ja)	2003-07-03	芳香族複素環を有するヒンバシン類縁体
WO2010015586A2 (en)	2010-02-11	2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds
HK1169411B (en)	2016-07-08	Methylpyrrolopyrimidinecarboxamides
WO2010015585A1 (en)	2010-02-11	6-benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds
WO2010015587A1 (en)	2010-02-11	5-benzyl-1,2,3,6-tetrahydro-4,6-diaza-cyclopenta[c]fluorene compounds and 5-benzyl-1,2,3,6-tetrahydro-4,6-diaza-cyclohepta[c]fluorene compounds